IP Library › Granted Patent US 12,186,453
Granted Patent B2
US 12,186,453 · App. 15/341,118 · Granted Jan 7, 2025

Materials with improved biocompatibility

Inventors: Arturo J. Vegas (Belmont, MA); Joshua C. Doloff (Quincy, MA); Omid Veiseh (Cambridge, MA); Robert S. Langer (Newton, MA); Daniel G. Anderson (Framingham, MA)
Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
A61L27/3804A61K9/0051A61K35/36A61K38/02A61L27/04A61L27/10A61L27/16A61L27/18A61L27/20A61L27/34A61L27/3813A61L27/3839A61L27/54A61L27/56A61L29/14C08J7/12A61K35/12A61K2035/128A61K35/39A61L2300/252A61L2300/254A61L2400/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,453
App. No.
15/341,118
Granted
Jan 7, 2025
Kind
B2
Abstract

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

Claims (22)

1. A macroscopic implant comprising a chemical moiety covalently bound to a polymer selected from polytetrafluoroethylene, polyurethane, polydimethylsiloxane, and poly(vinyl) chloride, wherein the polymer is present on a surface of the macroscopic implant, and wherein the chemical moiety is selected from the group consisting of:

2. The macroscopic implant of claim 1 , further comprising a cell that secretes a protein, wherein the macroscopic implant encapsulates the cell.

3. The macroscopic implant of claim 2 , wherein the cell is derived from a stem cell.

4. The macroscopic implant of claim 3 , wherein the cell is an insulin-producing cell.

5. The macroscopic implant of claim 1 , wherein the implant comprises a hollow fiber.

6. The macroscopic implant of claim 1 , wherein the implant is cylindrical.

7. The macroscopic implant of claim 1 , wherein the implant further comprises a pore having a pore size of between about 0.1 μm and about 1 μm.

8. The macroscopic implant of claim 1 , wherein the chemical moiety comprises:

9. The macroscopic implant of claim 1 , wherein the chemical moiety comprises:

10. The macroscopic implant of claim 1 , wherein the chemical moiety comprises:

11. The macroscopic implant of claim 1 , wherein the surface is an exterior surface.

12. The macroscopic implant of claim 1 , wherein the surface is an interior surface.

13. The macroscopic implant of claim 1 , wherein the surface is an exterior surface and the chemical moiety comprises

14. The macroscopic implant of claim 1 , wherein the surface is an interior surface and the chemical moiety comprises

15. The macroscopic implant of claim 4 , wherein the insulin producing cell is encapsulated by the polymer.

16. The macroscopic implant of claim 1 , wherein the macroscopic implant elicits a lower foreign body response following implantation compared to a corresponding macroscopic implant that lacks the chemical moiety.

17. The macroscopic implant of claim 1 , wherein the polymer is polytetrafluoroethylene.

18. The macroscopic implant of claim 1 , wherein the polymer is polyurethane.

19. The macroscopic implant of claim 1 , wherein the polymer is polydimethylsiloxane.

20. The macroscopic implant of claim 1 , wherein the polymer is poly(vinyl) chloride.

21. The macroscopic implant of claim 1 , wherein the implant is not a hydrogel.

22. A macroscopic implant comprising a chemical moiety covalently bound to a polymer selected from polyolefin, wherein the polymer is present on a surface of the macroscopic implant, and wherein the chemical moiety is selected from the group consisting of:

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2017
From: VEGAS, ARTURO J.; DOLOFF, JOSHUA C.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 042853/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2017
From: VEISEH, OMID; LANGER, ROBERT S.; ANDERSON, DANIEL G.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 042853/0270 →
CONFIRMATORY LICENSE Recorded Jun 28, 2017
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 043026/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: VEISEH, OMID; LANGER, ROBERT S.; ANDERSON, DANIEL G.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 042257/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: VEGAS, ARTURO J.; DOLOFF, JOSHUA C.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 042257/0565 →
Continuity (4)
Continuation PCTUS2016059966 · Nov 1, 2016
Provisional Application 62249323 · Nov 1, 2015
Related Publication 20180117216A1 · May 3, 2018
Related Publication 20190046690A9 · Feb 14, 2019
References Cited (123)
US 2881161A · Kohler · 1959 [cited by applicant]
US 2860130A · McNeely · 1985 [cited by applicant]
US 4816567A · Rock · 1989 [cited by applicant]
US 4868121A · Scharp · 1989 [cited by applicant]
US 5273904A · Langley · 1993 [cited by applicant]
US 5322790A · Scharp · 1994 [cited by applicant]
US 5336668A · dellaValle · 1994 [cited by applicant]
US 5443505A · Wong · 1995 [cited by examiner]
US 5447863A · Langley · 1995 [cited by applicant]
US 5622718A · Al-Shamkhani · 1997 [cited by applicant]
US 5624821A · Winter · 1997 [cited by applicant]
US 5821121A · Brothers · 1998 [cited by applicant]
US 5876452A · Athanasiou · 1999 [cited by examiner]
US 6159531A · Dang · 2000 [cited by applicant]
US 6194551B1 · Idusogie · 2001 [cited by applicant]
US 9422373B2 · Vegas · 2016 [cited by examiner]
US 10898443B2 · Vegas · 2021 [cited by examiner]
US 11090413B2 · Vegas · 2021 [cited by examiner]
US 20030113478A1 · Dang · 2003 [cited by applicant]
US 20040253532A1 · Wu · 2004 [cited by applicant]
US 20080003250A1 · Margulies · 2008 [cited by applicant]
US 20080044900A1 · Mooney · 2008 [cited by applicant]
US 20080177021A1 · Berlin · 2008 [cited by examiner]
US 20080242738A1 · Marks · 2008 [cited by applicant]
US 20080268189A1 · Sun · 2008 [cited by applicant]
US 20090148591A1 · Wang · 2009 [cited by applicant]
US 20090197791A1 · Balastre · 2009 [cited by applicant]
US 20110111004A1 · Barbieri · 2011 [cited by applicant]
US 20110319569A1 · Emrick · 2011 [cited by applicant]
US 20120009159A1 · Humayun · 2012 [cited by applicant]
US 20120041546A1 · Belcheva · 2012 [cited by applicant]
US 20120042456A1 · Jager Lezer · 2012 [cited by applicant]
US 20120083767A1 · Gerstenblith · 2012 [cited by applicant]
US 20120121657A1 · Zhou · 2012 [cited by applicant]
US 20120282299A1 · Delamarre · 2012 [cited by applicant]
US 20130149351A1 · Lee · 2013 [cited by applicant]
US 20130224276A1 · Hunter · 2013 [cited by applicant]
US 20150183939A1 · Lequeux · 2015 [cited by applicant]
US 20150368713A1 · Bharti · 2015 [cited by applicant]
US 20160030360A1 · Vegas · 2016 [cited by examiner]
US 20170014776A1 · Li · 2017 [cited by applicant]
US 20170226232A1 · Vegas · 2017 [cited by examiner]
US 20170239397A1 · Vegas · 2017 [cited by examiner]
US 20170246347A1 · Vegas · 2017 [cited by examiner]
US 20220031913A1 · Vegas · 2022 [cited by examiner]
CN 101565469 · 2009 [cited by applicant]
DE 102005049833 · 2007 [cited by applicant]
EP 1614696 · 2006 [cited by applicant]
FR 2699545 · 1994 [cited by applicant]
GB 676618 · 1952 [cited by applicant]
GB 768309 · 1957 [cited by applicant]
WO WO9900070 · 1999 [cited by applicant]
WO WO9958572 · 1999 [cited by applicant]
WO WO2003010354 · 2003 [cited by applicant]
WO 03085372 · 2003 [cited by applicant]
WO 2005058382 · 2005 [cited by applicant]
WO 2005063147 · 2005 [cited by applicant]
WO 2009032158 · 2009 [cited by applicant]
WO 2010090767 · 2010 [cited by applicant]
WO WO2012167223 · 2012 [cited by applicant]
WO WO2012167223A1 · 2012 [cited by examiner]
WO 2013121983 · 2013 [cited by applicant]
WO 2014044697 · 2014 [cited by applicant]
WO 2014052080 · 2014 [cited by applicant]
WO 2015054484 · 2015 [cited by applicant]
WO 2015187204 · 2015 [cited by applicant]
WO WO2016019391 · 2016 [cited by applicant]
Pedraza, E. “Engineering an optimal bioartificial pancreas for islet transplantation using bioactive scaffolds” Ph.D. dissertation, University of Miami, 2011. (Year: 2011). [cited by examiner]
Chen et al. World Journal of Gastroenterology, 2004, 10(20), 3016-3020. (Year: 2004). [cited by examiner]
Kovach (J. of Biomedical Material Research Pt. A, 2014, 102A, 4195-4205) (Year: 2014). [cited by examiner]
Pedraza, E. et al. “Preventing hypoxia-induced cell death . . . ” Proceedings of the National Academy of Sciences (PNAS), 2012, 109(11), 4245-4250. (Year: 2012). [cited by examiner]
Anderson, P.D. et al. “Conotoxins: Potential weapons from the sea” J. Bioterr. Biodef., 2012, 3:120 doi:10.4172/2157-2526.1000120. No pagination (4 pages). (Year: 2012). [cited by examiner]
Chem Europe “Hexazine”, https://www.chemeurope.com/en/encyclopedia/Hexazine.html, no pagination, no date available. [cited by examiner]
Lee et al. (Langmuir, 2005, 21, 11957-11962) (Year: 2005). [cited by examiner]
Pedraza et al. J. of Biomaterials Science—Polymer Edition, 2013, 9, 1041-1056, published online Oct. 2012. [cited by examiner]
Anderson, et al., “Foreign body reaction to biomaterials”, [cited by applicant]
Costa, et al., “Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces”, [cited by applicant]
Field, et al., “Improved islet isolation from rat pancreas using 35% bovine serum albumin in combination with Dextran gradient separation”, [cited by applicant]
Grainger, “All charged up about implanted biomaterials”, [cited by applicant]
Gruber, et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in [cited by applicant]
Harding and Reynolds, “Combating medical device fouling”, [cited by applicant]
Hetrick, et al., “Reduced foreign body response at nitric oxide-releasing subcutaneous implants”, [cited by applicant]
Hollinger, et al., ““Diabodies”: small bivalent and bispecific antibody fragments”, [cited by applicant]
Hudalla, et al., “Immobilization of peptides with distinct biological activities onto stem cell culture substrates using orthogonal chemistries”, [cited by applicant]
Langer, “Perspectives and challenges in tissue engineering and regenerative medicine”, [cited by applicant]
Linetsky, et al., “Improved human islet isolation using a new enzyme blend, liberase”, [cited by applicant]
Poncin, et al., “Comparing and Optimizing Co—Cr Tubing for Stent Applications,” Materials & Processes for Medical Devices Conference, ASM International, pp. 1-6, Aug. 2004. [cited by applicant]
Ratner, “Reducing capsular thickness and enhancing angiogenesis around implant drug release systems”, [cited by applicant]
Rodriguez, et al., “Quantitative in vivo cytokine analysis at synthetic biomaterial implant”, [cited by applicant]
Sussman, et al., “Porous Implants Modulate Healing and Induce Shifts in Local Macrophage Polarization in the Foreign Body Reaction”, [cited by applicant]
Thevenot, et al., “Surface chemistry influences implant biocompatibility”, Curr Top Med Chem., 8(4):270-80 (2011). [cited by applicant]
Ward, “A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis”, [cited by applicant]
Wick, et al., “The immunology of fibrosis”, [cited by applicant]
Williams, “On the mechanisms of biocompatibility”, [cited by applicant]
Wynn and Ramalingam, “Mechanisms of fibrosis: therapeutic translation for fibrotic disease”, [cited by applicant]
Zhang, et al., “Zwitterionic hydrogels implanted in mice resist the foreign-body reaction”, [cited by applicant]
International Search Report for corresponding PCT application PCT/US2016/059966 mailed Mar. 4, 2017. [cited by applicant]
Wikstrom, “Alginate-based microencapsulation of retinal pigment epithelial cell line for cell therapy”, [cited by applicant]
Vallee, et al., “Synthesis and rheological properties of hydrogels based on amphiphilic alginate-amide derivatives”, Carbohydrate Res., 344:223-8 (2009). [cited by applicant]
Extended European Search Report issued for EP 18 16 2427 mailed Jun. 19, 2018. [cited by applicant]
Ahad, et al., “Surface modification of polymers for biocompatibility via exposure to extreme ultraviolet radiation”, Society for Biomaterials, 3296-3310 (2013). [cited by applicant]
Chen, “Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells”, World Journal of Gastroenterology, 10(20): 3016-3020 (2004). [cited by applicant]
Chen, et al., “Multifunctional Biocompatible Membrane and Its Application to Fabricate A Miniaturized Glucose Sensor with Potential for Use in Vivo”, Biomedical Microdevices, 1(2):155-166 (1998). [cited by applicant]
Chu, et al., “A soft and flexible biosensor using a phospholipid polymer for continuous glucose monitoring”, Biomedical Microdevices, 11(4):837-842 (2009). [cited by applicant]
Cui, et al., “Electrochemical deposition and characterization of poly (3, 4-ethylenedioxythiophen) on neural microelectrode arrays”, Sensors and Actuators B, 89:92-102 (2003). [cited by applicant]
Hersel, et al., “RGD modified polymers: biomaterials for stimulated cell adhesion and beyond”, Biomaterials, 24(24):4385-4415 (2003). [cited by applicant]
Huh, et al., “From 3D cell culture to organs-on chips”, Trends in Cell Biology, 21(12):745-754 (2011). [cited by applicant]
Lee, et al., “Development and characterization of an alginate-impregnated polyester vascular graft”, Journal of Biomed. Mater. Research, 36(2):200-208 (1996). [cited by applicant]
Skousen, et al. “A strategy to passively reduce inflammation surrounding devices implanted chronically brain tissue by manipulating device surface permeability”, Biomaterials, 36:33-43 (2015). [cited by applicant]
Sun, et al., “Functionalization of quantum dots with multidentate zwitterionic ligands: impact on cellular interactions and cytotoxicity”, Journal of Materials Chemistry B, 1(44): 6137 (2013). [cited by applicant]
West, et al., “The biocompatibility of crosslinkable copolymer coatings containing sulfobetaines and phosphobetaines”, Biomaterials, 25(7-8):1195-1204 (2004). [cited by applicant]
Yang, et al., “Zwitterionic poly(carboxybetaine) hydrogels for gluclose biosensors in complex media”, Biosensors and Bioelectronics, 26(5):2454-2459 (2011). [cited by applicant]
Ratner, “A pore way to heal and regenerate: 21st century thinking on biocompatibility”, Regenerative Biomaterials, 107-110 (2016). [cited by applicant]
DeVos, et al., “Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets”, Diabetologia, 40(3):262-270 (1997). [cited by applicant]
Gattas-Asfura, “Chemoselective cross-linking and functionalization of alginate via Staudinger ligation”, Biomacromolecules, 10:3122-3129 (2009). [cited by applicant]
Hall, et al., “Microencapsulation of islets within alginate/poly)ethylene glycol) gels cross-linked via Staudinger ligation”, Acta Biomaterialia, 7:614-24 (2011). [cited by applicant]
Pedraza, et al., “Macroporous three-dimensional PDMS scaffolds for extrahepatic islet transplantation”, Cell Transplantation, 22:1123-1135 (2013). [cited by applicant]
Tang, et al., “Reprogramming liver-stem WB fcells into functional insulin-prodcuing cells by persistent expression of Pdx1-and Pdx1-VP16 mediated by lentiviral vectors”, Lab Invest 86(1)83-93 (2006). [cited by applicant]
Yang, et al., “Research progress on chemical modification of alginate: A review”, Carbohydrate Polymers, 84(1):33-39 (2011b). [cited by applicant]
Yimin, et al., “Alginic Acid”, 137-140. [cited by applicant]
Belikov, et al., Pharmaceutical Chemistry, Moscow, Higher School, 43-47 (1993). [cited by applicant]
Mørch, et al., “Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads”, Biomacromolecules, 7(5): 1471-1480 (2006). [cited by applicant]
Sun, “Microencapsulation of pancreatic islet cells: a bioartificial endocrine pancreas”, Methods in Enzymology, 137:575-580 (1988). [cited by applicant]